RT Journal Article
T1 Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
A1 Fraile-Ribot, Pablo A.
A1 Zamorano, Laura
A1 Orellana, Rocio
A1 Del Barrio-Tofiño, Ester
A1 Sanchez-Diener, Irina
A1 Cortes-Lara, Sara
A1 Lopez-Causape, Carla
A1 Cabot, Gabriel
A1 Bou, German
A1 Martinez-Martinez, Luis
A1 Oliver, Antonio
K1 Pseudomonas aeruginosa
K1 Antibiotic resistance
K1 Extensively drug resistant
K1 Imipenem-relebactam
K1 Multidrug resistance
K1 Whole-genome sequencing
K1 β-lactam resistance mechanisms
AB Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC.
PB ASM Journals
YR 2019
FD 2019-11-14
LK http://hdl.handle.net/10668/14708
UL http://hdl.handle.net/10668/14708
LA en
NO Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, et al. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e02165-19
NO The work was supported by MSD and by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), and grant PI18/00076 cofinanced by European Regional Development Fund (ERDF) “A way to achieve Europe,” Operative Program Intelligent Growth 2014 –2020. The work was partially financed by MSD through Investigator Initiated Studies Program to A.O. 
DS RISalud
RD Jul 20, 2025